these various growth factors may cooperate together to provide optimum signalling, eventually because ther are colocalized together and with cytoplasmic transduction elements in caveolin-linked membrane caveolae.
The identification of these myeloma cell growth factors and of the associated transduction pathways should provide novel therapeutic targets in multiple myeloma.
Since 15 years, numerous studies have been devoted to the study of myeloma growth factors.
These myeloma growth factors may be specific to the myeloma clone or involved in the generation of normal plasma cells. In a first part, we will briefly review the recent knowledge of the biology of normal plasma cells and then discuss the major growth factors involved in multiple myeloma (MM). that can be involved in the prolonged survival of mature plasma cells 4 .
Biology of normal plasma cells
As illustrated up in Figure 1 , memory B cells express Bcl-6 and Pax-5 whereas these transcription factors are donwregulated in plasmablastic cells. On the contrary, plasmablastic cells expressed the plasma cell transcription factors Blimp-1 and XBP-1. Actually, according 9 In addition, transgenic mice expressing an IL-6 gene driven by an Eµ promoter develop massive polyclonal plasmacytosis 10 whereas IL-6 knock out mice have a defect in the production of high affinity antibodies. 
Myeloma cell survival and proliferation factors
Numerous studies have been devoted to the identification of myeloma cell growth factors and to the signalling pathways leading to survival and/or proliferation of myeloma cells. A first category of factors activates the JAK/STAT and MAP kinase pathways (mainly IL-6).
Another category involves the PI-3 kinase/AKT as well as MAPkinase and NF-kappa B pathways.
Factors activating the JAK/STAT and MAP kinase pathways: IL-6, cytokines of IL-6 family, interferon alpha
IL-6 binds to a specific receptor (IL-6R) and the complex IL-6/IL-6R binds and induces the homodimerization of the gp130 IL-6 transducer. 13 A remarkable feature of IL-6R is that its soluble form (sIL-6R) is an agonist molecule. It binds IL-6 with the same affinity as membrane IL-6R and the complex IL-6/sIL-6R binds and activates gp130. 13 The evidences of a major role of IL-6 in the survival and proliferation of malignant plasma cells accumulated since the initial reports by others and us 15 years ago. 14, 15 These evidences are the following:
1) Antibodies to IL-6 block the myeloma cell proliferation and reduce by 50% the number of myeloma cells in culture of patients' bone marrow cells in vitro [14] [15] [16] 2) Injection of anti-IL-6 monoclonal antibody inhibited myeloma cell proliferation in patients with terminal disease 17, 18 if the antibody was injected at a sufficient concentration to block the large IL-6 production in vivo. 19 3) Serum levels of IL-6 and soluble IL-6R are increased in patients with MM in association with a poor prognosis. 20, 21 4) The bone marrow environment of patients with MM, mainly by monocytes, myeloid cells and stromal cells, overproduces IL-6. 15, 22 This production of IL-6 by the tumor environment is mostly mediated by IL-1 that is produced by monocytes and myeloma cells. 22, 23 IL-1 induces PGE2 synthesis that further triggers IL-6 production. 23 Thus inhibitors of IL-1 as the IL-1 receptor antagonists or of PGE2 synthesis might be interesting to block IL-6 production in patients with MM. A similar mechanism was shown in the model of murine plasmacytoma in BALB/C mice. The generation of plasmacytomas was blocked by chronic administration of indomethacin that inhibited PGE2 synthesis and the large IL-6 production by the inflammatory environment. 24 Myeloma cells can also directly trigger IL-6 production by direct contact with the bone marrow stromal cells by unidentified mechanisms. 25, 26 5) Cell lines whose survival is dependent on addition of exogenous IL-6 can be obtained from patients with extramedullary proliferation. 27 6) Mice transgenic with an IL-6 gene driven by the Eµ promoter develop massive polyclonal plasmacytosis. 28 When crossed with murine BALB/c mice that spontaneously develop plasmacytomas, these crossed mice develop malignant plasma cell prolferation. 29 In addition, knock out of IL-6 gene abrogated the generation of malignant plasmacytomas in BALB/C mice primed with mineral oil. 30 Other cytokines of the IL-6 family are also myeloma cell growth factors due to the expression of specific receptors: OSM, CNTF, IL-11, LIF. 31 But these factors are likely not involved in the emergence of the disease in vivo as they are weakly produced by the tumor or its environment. 32 In our hands, interferon-alpha (IFNα) is also a myeloma cell survival factor that is independent of IL-6. 33, 34 IFNα activated the JAK/STAT and MAP kinase pathways as IL-6, in particular STAT3 phosphorylation. 34 Other groups found that IFNα could block myeloma cell proliferation. This discrepancy might be explained by the ability of IFNα to induce P19 inhibitor in some cell lines yielding to apoptosis. 35 Finally, we found that IL-10, a potent plasma cell differentiation factor, is also a myeloma cell growth factor. 36 IL-10 works through induction of autocrine loops of IL-6 family cytokines. apoptotic proteins, we found that only Mcl-1 was regulated by IL-6 or IFNα. 39 Other groups suggested that bcl-xL was the main anti-apoptotic protein controlled by IL-6 in myeloma cells 40, 41 but a recent study emphasizes that only a blockade of Mcl-1, unlike bcl-2 or bcl-xL could inhibit myeloma cell survival. 42 In addition, we found that induction of the constitutive production of Mcl-1 by retroviral vector is sufficient to promote myeloma cell proliferation independently of IL-6 43 . IL-6 was reported to activate AKT kinase in myeloma cells that is able to trigger various signalling pathways. 44 AKT activation can be mediated by STAT3 phosphorylation and ras pathway that can trigger PI-3 kinase activation. 45 In our experience, we found a weak AKT phosphorylation in only some IL-6-dependent cell lines (results not shown). Actually, the IL-6-induced AKT phosphorylation in myeloma cells is weak and transient as compared to that induced by IGF-1. 46 PI-3 kinase mediated AKT phosphorylation appears critical in promoting proliferation of myeloma cell lines since PI-3 kinase inhibitors abrogate it unlike MAP kinase inhibitors. 47, 48 These transduction pathways activated by IL-6 and other myeloma cell growth factors are schematized in the figure 2. pathway. 51, 52 IGF-1 induced the PI-3 kinase pathway and in particular the phosphorylation of AKT protein. 44, 52 IGF-1 also induces MAP kinase phosphorylation. 51, 52 The myeloma growth factor activity of IGF-1 is blocked by an inhibitor of PI-3 kinase pathway unlike a MAP kinase inhibitor. 47, 48 One mechanism of action of AKT is the phosphorylation of the pro-apoptotic protein Bad that induces its sequestration by the 14-3-3 protein and prevents its migration to mitochondrial membrane. 52, 53 Other proteins are phosphorylated by the PI-3 kinase/AKT pathway in myeloma cells: the P70S6-kinase, forkhead proteins and the glycogen synthase kinase-3 beta (GSK3β). 47, 48, 53 Phosphorylation of these proteins contributes to blockade of apoptosis and activation of cell cycle in various models. In particular, IGF-1 induces cyclin D1 and Skp2 expression and downregulation of P27kip1 in myeloma cells. A hallmark of plasma cell differentiation is the expression of the proteoglycan syndecan-1. 59, 60 This heparan-sulfate protein has many biological activities and in particular, is able to bind heparin-binding growth factors and to present them to their specific receptors. 61 Thus, it
is not surprising that several recently-reported myeloma cell growth factors are heparinbinding growth factors.
Heparin-binding epidermal growth factor like growth factor (HB-EGF). Using Atlas macroarrays, we found that myeloma cell lines overexpressed HB-EGF gene compared to EBV-transformed B cell lines or normal plasmablastic cells and that inhibitors of HB-EGF
can block the IL-6-dependent survival of these myeloma cell lines. 58 Actually, we found that HB-EGF cooperates with IL-6 to trigger an optimal survival of myeloma cells, likely through an interaction between the transducer chains, gp130 and EGF receptors. 62 HB-EGF can activate two of the four members of the EGF receptor family, ErbB1 and ErbB4, which are variably express by myeloma cells. HB-EGF triggers the PI-3K/AKT pathway in myeloma cells, unlike STAT3 phosphorylation (unpublished data). Several coreceptors can enhance the binding of HB-EGF and increase its biological activity: syndecan-1, the tetraspanin CD9 and the integrin α3β1. 79 These data suggest that BAFF inhibitor could be useful in the treatment of patients with MM in association with dexamethasone.
Cross-activation of growth factor receptors and potential clinical applications
The contribution of these various myeloma growth factors to myeloma disease can be simplified by considering the transduction pathways that are critical to promote myeloma survival and cell cycle. As indicated above, at least four transduction cascades are activated by these various factors, the JAK/STAT pathway induced by IL-6 cytokines and IFNα, the PI-3 kinase/AKT pathway strongly activated by IGF-1 and heparin binding factors and weakly induced by IL-6, the NF-kappa B pathway activated by IGF-1 and BAFF proteins and the MAP kinase pathway induced by all factors. We recently pointed out cooperation between IL-6 and HB-EGF to trigger myeloma cell survival and proliferation. 62 The effect of HB-EGF is dependent on weak gp130 activation by IL-6. This cooperation likely reflects a cross talk of the transduction elements and activation of various anti-apoptotic proteins. 62 This was recently shown for gp130 IL-6 transducer and IFN receptor or IGF receptor. Indeed, Jelinek's group showed that IFN-α could activate the phosphorylation of endogenous gp130.
This cross-activation is not reciprocal as IL-6 cannot cross-phosphorylate endogenous IFN receptor. 80 The same group also showed that IFNα induced a cross-phosphorylation of endogenous ErbB3 receptor in a myeloma cell line. 81 This ability of IFNα to induce these cross-phosphorylations of other transducer chains unlike IL-6 or IGF-1, is linked to its ability to trigger a large and long-lasting activation of JAK1 and Tyk2 kinases compared to IL-6. 
